NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
PLX
Protalix BioTherapeutics, Inc.
PLX has the edge over NVO overall, supported by stronger fundamentals and stronger valuation.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PLX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
PLX's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over PLX in the historical PE scenario, which offers more potential upside but is not a forecast.
PLX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 11x | $2.96 | — |
| Cheap | 12x | $3.21 | +8.4% |
| Forward | 25x | $2.96 | — |
| Fair | 26x | $6.68 | +126% |
| Expensive | 43x | $11.27 | +281% |
Historical ranges are pointers, not guarantees.
PLX's PE is in its cheap range at 11x. On analysts' estimates for next year's earnings, today's price would be 25x, in its fair range.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PLX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
PLX has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PLX on earnings, with more consistent year-over-year improvement.
PLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.12 | -54% |
| Q3 2026 | $0.26 | +225% |
| Q2 2026 | $0.24 | +200% |
| Q1 2026 | $0.19 | +280% |
| Q4 2025 | -$0.08 | -300% |
| Q3 2025 | $0.08 | +$0.17 |
| Q2 2025 | $0.08 | +$0.24 |
| Q1 2025 | $0.05 | -38% |
| Q4 2024 | $0.04 | -56% |
PLX's earnings per share have jumped to their highest in six years: $0.26 over the past year, up from $0.08 the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PLX on profitability, with a higher operating margin.
PLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $21.9M | +23% |
| Q2 2026 | $19.9M | +27% |
| Q1 2026 | $33.8M | +234% |
| Q4 2025 | $9.1M | -50% |
| Q3 2025 | $17.9M | -0.6% |
| Q2 2025 | $15.7M | +16% |
| Q1 2025 | $10.1M | +170% |
| Q4 2024 | $18.2M | +74% |
PLX's revenue is recovering but still below its 2023 peak: $22M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +6.5 points |
| Q2 2026 | 23% | +16 points |
| Q1 2026 | 63% | +104 points |
| Q4 2025 | -51% | -91 points |
| Q3 2025 | 12% | -10 points |
| Q2 2025 | 7.5% | +26 points |
| Q1 2025 | -41% | +89 points |
| Q4 2024 | 40% | +93 points |
PLX's operating margin was 18% last quarter, up 6.5 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PLX on cash flow, with more consistent year-over-year improvement.
PLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.2M | +$7.4M |
| Q2 2026 | -$11M | -$5.3M |
| Q1 2026 | $21.3M | +$26.6M |
| Q4 2025 | $1.6M | -54% |
| Q3 2025 | -$4.2M | -205% |
| Q2 2025 | -$5.7M | -$1.9M |
| Q1 2025 | -$5.4M | -249% |
| Q4 2024 | $3.6M | +6.6% |
PLX's free cash flow has turned positive again: $15M over the past year, against −$12M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PLX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1M shares |
| 1 year | +3.4% | +2.8M shares |
| 3 years | -0.2% | -196K shares |
| 5 years | +84% | +38.1M shares |
| Available history | +463% | +68.7M shares |
PLX has 84M diluted shares, up 3.4% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PLX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.9x | Net Cash |
| Q1 2025 | -3.3x | Net Cash |
| Q4 2024 | -3.8x | Net Cash |
| Q1 2024 | -2.9x | Net Cash |
PLX has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.4 | Neutral |
| Stochastic | 65.9 | Neutral |
PLX's weekly RSI is 65 (neutral) and its Stochastic is 66 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over PLX on valuation relative to its sector.
PLX PE vs Healthcare Sector
| Metric | PLX | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 56% below |
| PE % | 13 | 29 | 16 pts below |
PLX is trading at 11x earnings, a 56% discount to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 10% above |
| 20 week MA | $2.55 | 16% above |
| 50 week MA | $2.35 | 26% above |
| 100 week MA | $2.18 | 36% above |
| 200 week MA | $1.87 | 58% above |
PLX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.79 | $3.44 | +23% |
| 2021 | $3.44 | $0.95 | -72% |
| 2022 | $0.95 | $1.18 | +24% |
| 2023 | $1.18 | $1.78 | +51% |
| 2024 | $1.78 | $1.83 | +2.8% |
| 2025 | $1.83 | $1.81 | -1.1% |
| 2026 YTD | $1.81 | $2.96 | +64% |
PLX has the edge over NVO on returns for 2026, with the stronger performance.